Erlotinib clinical trials

Erlotinib is a selective, reversible tyrosine kinase inhibitor which binds with high affinity to the mutated EGFR receptor, thus preventing promotion of tumour cell survival and proliferation.1

Please click below for more information on the key clinical trials that demonstrate
erlotinib's safety and efficacy profile in the first-line treatment of EGFR Mut+ NSCLC.

OPTIMAL phase III trial
(Chinese patients)
EURTAC phase III trial
(European patients)
ENSURE phase III trial
(Asian patients)